Robert Dunn, MD, PhD, as the Chief Scientific Officer for Clinilabs. With two decades of experience in clinical development and neuroscience research, Bob is a prominent figure in the field of CNS research. He has directed and designed clinical studies in various indications ranging from Phase I to Phase IV. He has worked with key opinion leaders, vendors, and interdisciplinary teams on various neuroscience projects. Bob has expertise in psychiatric indications such as unipolar depression, schizophrenia, bipolar depression, anxiety, and autism. He has previously held positions at Pfizer, Forest Research Institute, and Forum Pharmaceuticals, and was also an Assistant Professor at Harvard Medical School. Bob has obtained his MD and PhD in Pharmacology and Physiology from the University of Chicago Pritzker School of Medicine. His ultimate goal is to provide innovative and effective solutions to people suffering from psychiatric and neurological illnesses.

< Back to Leadership Team